In vivo evidence for an instructive role of fms-like tyrosine kinase-3 (FLT3) ligand in hematopoietic development

被引:41
|
作者
Tsapogas, Panagiotis [1 ]
Swee, Lee Kim [2 ]
Nusser, Anja [1 ]
Nuber, Natko [1 ]
Kreuzaler, Matthias [1 ]
Capoferri, Giuseppina [1 ]
Rolink, Hannie [1 ]
Ceredig, Rhodri [3 ]
Rolink, Antonius [1 ]
机构
[1] Univ Basel, Dept Biomed, CH-4003 Basel, Switzerland
[2] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA
[3] Natl Univ Ireland, Regenerat Med Inst, Dept Physiol, Sch Med Nursing & Hlth Sci, Galway, Ireland
基金
瑞士国家科学基金会;
关键词
COMMON LYMPHOID PROGENITORS; INTERNAL TANDEM DUPLICATION; DENDRITIC CELLS; STEM-CELL; MURINE FLT3; SELF-RENEWAL; RECEPTOR; EXPRESSION; EXPANSION; IDENTIFICATION;
D O I
10.3324/haematol.2013.089482
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytokines are essential regulators of hematopoiesis, acting in an instructive or permissive way. Fms-like tyrosine kinase 3 ligand (FLT3L) is an important cytokine for the development of several hematopoietic populations. Its receptor (FLT3) is expressed on both myeloid and lymphoid progenitors and deletion of either the receptor or its ligand leads to defective developmental potential of hematopoietic progenitors. In vivo administration of FLT3L promotes expansion of progenitors with combined myeloid and lymphoid potential. To investigate further the role of this cytokine in hematopoietic development, we generated transgenic mice expressing high levels of human FLT3L. These transgenic mice displayed a dramatic expansion of dendritic and myeloid cells, leading to splenomegaly and blood leukocytosis. Bone marrow myeloid and lymphoid progenitors were significantly increased in numbers but retained their developmental potential. Furthermore, the transgenic mice developed anemia together with a reduction in platelet numbers. FLT3L was shown to rapidly reduce the earliest erythroid progenitors when injected into wild-type mice, indicating a direct negative role of the cytokine on erythropoiesis. We conclude that FLT3L acts on multipotent progenitors in an instructive way, inducing their development into myeloid/lymphoid lineages while suppressing their megakaryocyte/erythrocyte potential.
引用
收藏
页码:638 / 646
页数:9
相关论文
共 50 条
  • [1] FMS-LIKE TYROSINE KINASE 3/FLT3: FROM BASIC SCIENCE TO CLINICAL IMPLICATIONS
    Kazi, Julhash U.
    Ronnstrand, Lars
    PHYSIOLOGICAL REVIEWS, 2019, 99 (03) : 1433 - 1466
  • [2] FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies
    Mashkani, Baratali
    Tanipour, Mohammad Hossein
    Saadatmandzadeh, Mohammad
    Ashman, Leonie K.
    Griffith, Renate
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 776 : 156 - 166
  • [3] FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
    Hasegawa, Hiroko
    Taniguchi, Hiroya
    Nakamura, Yoshiaki
    Kato, Takeshi
    Fujii, Satoshi
    Ebi, Hiromichi
    Shiozawa, Manabu
    Yuki, Satoshi
    Masuishi, Toshiki
    Kato, Ken
    Izawa, Naoki
    Moriwaki, Toshikazu
    Oki, Eiji
    Kagawa, Yoshinori
    Denda, Tadamichi
    Nishina, Tomohiro
    Tsuji, Akihito
    Hara, Hiroki
    Esaki, Taito
    Nishida, Tomohiro
    Kawakami, Hisato
    Sakamoto, Yasutoshi
    Miki, Izumi
    Okamoto, Wataru
    Yamazaki, Kentaro
    Yoshino, Takayuki
    CANCER SCIENCE, 2021, 112 (01) : 314 - 322
  • [4] Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia
    Nazha, Aziz
    Cortes, Jorge E.
    Faderl, Stefan
    Pierce, Sherry
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Ferrajoli, Alessandra
    Kadia, Tapan
    Borthakur, Gautam
    Luthra, Rajyalakshmi
    Kantarjian, Hagop M.
    Ravandi, Farhad
    BLOOD, 2011, 118 (21) : 1518 - 1518
  • [5] Fms-like tyrosine kinase 3 (Flt3) ligand depletes erythroid island macrophages and blocks medullar erythropoiesis in the mouse
    Jacobsen, Rebecca N.
    Nowlan, Bianca
    Brunck, Marion E.
    Barbier, Valerie
    Winkler, Ingrid G.
    Levesque, Jean-Pierre
    EXPERIMENTAL HEMATOLOGY, 2016, 44 (03) : 207 - 212
  • [6] Efficacy of FMS-like Tyrosine Kinase 3 (FLT3) inhibitors in patients with acute myeloid leukemia
    Htut, T. W.
    Ball, S.
    Khandelwal, N.
    Wongsaengsak, S.
    Mogollon-Duffo, F.
    Jahan, N.
    Quirch, M.
    D'cunha, N.
    Thein, K. Z.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 52 - 53
  • [7] FMS-like Tyrosine Kinase 3 (FLT3) Gene as a Significant Biomarker for Acute Myeloid Leukemia
    Fotra, Roopali
    Kour, Jyotdeep
    Mahajan, Deepti
    Kumar, Parvinder
    Dhar, Manoj K.
    BIOSCIENCE BIOTECHNOLOGY RESEARCH COMMUNICATIONS, 2020, 13 (01): : 280 - 283
  • [8] Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges
    Sternberg, DW
    Licht, JD
    CURRENT OPINION IN HEMATOLOGY, 2005, 12 (01) : 7 - 13
  • [9] 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)
    Hsu, John T. -A.
    Yeh, Teng-Kuang
    Yen, Shih-Chieh
    Chen, Chiung-Tong
    Hsieh, Shu-Yi
    Hsu, Tsu
    Lu, Cheng-Tai
    Chen, Chun-Hwa
    Chou, Ling-Hui
    Chiu, Ching-Hui
    Chang, Yun-I
    Tseng, Ya-Ju
    Yen, Kuei-Rong
    Chao, Yu-Sheng
    Lin, Wen-Hsing
    Jiaang, Weir-Torn
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (14) : 4654 - 4659
  • [10] ALTERATION OF LPS SIGNALING PATHWAYS IN DENDRITIC CELLS BY FMS-LIKE TYROSINE KINASE-3 LIGAND
    Toliver-Kinsky, T.
    Cui, W.
    Sherwood, E.
    SHOCK, 2010, 33 : 24 - 24